Novocure Ltd (NVCR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.38B
Last updated: Nov 17, 2026 at 4:20 PM ET
Novocure Ltd (NVCR) Statistics
Novocure (NVCR) has a market cap of $1.38B and an enterprise value of $1.48B. Its share count is up 4.36% from a year earlier. It kept -16.78% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 7.20% above the market cap, as debt exceeds cash.
| Market Cap | $1.38B |
|---|---|
| Enterprise Value | $1.48B |
| Latest price (Nov 17, 2026) | $11.14 |
Key Dates
| Last Earnings Date | Oct 29, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 1.8x and 3.7x. Its year-end P/S ranged from 2.2x to 36.2x from 2016 to 2025.
| P/S Ratio | 1.8x |
|---|---|
| Forward P/S | 1.9x |
| P/B Ratio | 3.7x |
Price Statistics
The stock is down 1.59% over 52 weeks and trades 23.65% below its 50-day average.
| Beta (1Y) | 1.52 |
|---|---|
| 52-Week Change | -1.59% |
| 1-Month Change | -25.18% |
| 3-Month Change | -38.79% |
| 6-Month Change | -34.51% |
| 5-Year Change | -87.18% |
| 10-Year Change | +117.36% |
| Total Return (1Y) | -1.59% |
| Total Return (3Y CAGR) | -3.43% |
| Total Return (5Y CAGR) | -36.62% |
| Return vs SPY (1Y) | -14.27% |
| Max Drawdown (1Y) | -44.27% |
| Max Drawdown (3Y) | -69.98% |
| Sharpe Ratio (1Y) | -0.04 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $14.59 |
| 200-Day Average | $14.78 |
| 52-Week Range | $9.82 to $21.45 |
| RSI (14 Days) | 29.9 |
| Average Volume (20 Days) | 1.96M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.49x current liabilities, and total debt is 0.56x shareholder equity.
| Current Ratio | 2.49x |
|---|---|
| Quick Ratio | 2.34x |
| Debt / Equity | 0.56x |
Returns and Efficiency
Return on invested capital is -21.23% over the last 12 months, against a 5-year average of -23.50%.
| Return on Equity (ROE) | -34.72% |
|---|---|
| Return on Assets (ROA) | -14.69% |
| Return on Invested Capital (ROIC) | -21.23% |
| Return on Capital Employed (ROCE) | -22.32% |
| ROE (5Y Average) | -35.83% |
| ROA (5Y Average) | -12.30% |
| ROIC (5Y Average) | -23.50% |
| Asset Turnover | 0.66x |
| Inventory Turnover | 4.03x |
| Receivables Turnover | 7.00x |
| Cash Conversion Cycle | -160 days |
Scores
NVCR has an Altman Z-Score of 0.25, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.25 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $725.39M over the last 12 months is up 12.94% from the 12 months before.
| Revenue | $725.39M |
|---|---|
| Revenue Growth (YoY) | +12.94% |
| Gross Profit | $558.67M |
| Operating Income | -$124.55M |
| Pretax Income | -$130.54M |
| Net Income | -$121.73M |
| EBITDA | -$119.05M |
| EBIT | -$124.55M |
| Reported EPS (TTM) | -$1.06 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 42.31% of the $828.71M in total assets.
| Cash and Equivalents | $96.73M |
|---|---|
| Total Debt | $196.34M |
| Net Debt | $99.60M |
| Net Debt Per Share | $0.85 |
| Working Capital | $402.86M |
| Shareholder Equity | $350.61M |
| Book Value Per Share | $3.00 |
| Total Assets | $828.71M |
| Total Liabilities | $478.10M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $23.89M of capital spending, operating cash flow left -$24.61M of free cash flow.
| Operating Cash Flow | -$722.00K |
|---|---|
| Capital Expenditures | $23.89M |
| Free Cash Flow | -$24.61M |
| FCF Per Share | -$0.21 |
| Depreciation and Amortization | $28.63M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -17.17%, against a 5-year average of -24.46%.
| Gross Margin | 77.02% |
|---|---|
| Operating Margin | -17.17% |
| Pretax Margin | -18.00% |
| Net Margin | -16.78% |
| EBITDA Margin | -16.41% |
| EBIT Margin | -17.17% |
| FCF Margin | -3.39% |
| Gross Margin (5Y Average) | 76.77% |
| Operating Margin (5Y Average) | -24.46% |
| Net Margin (5Y Average) | -23.48% |
Growth
Revenue grew 6.81% a year over 3 years.
| Revenue Growth (3Y CAGR) | +6.81% |
|---|---|
| Revenue Growth (5Y CAGR) | +5.80% |
| Book Value Per Share Growth (2Y CAGR) | -5.06% |
| Tangible Book Per Share Growth (2Y CAGR) | -5.06% |
Dividends and Yields
NVCR does not pay a dividend. Its free cash flow yield is -1.89%.
| FCF Yield | -1.89% |
|---|---|
| Buyback Yield | -0.28% |
| Shareholder Yield | -0.28% |
Peer Position
Against 12 similar companies, NVCR has the 8th highest P/S.
P/S RatioPeer median 1.9x
ROICPeer median -3.43%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.41%
| P/S Ratio | 1.8x vs 1.9x median |
|---|---|
| ROIC | -21.23% vs -3.43% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +12.94% vs +10.41% median |
Analyst Forecast
Consensus estimates put revenue growth at 11.12% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +11.12% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About NVCR
What is NVCR's market cap?
Novocure has a market cap of $1.38B. Its enterprise value, which adds debt and subtracts cash, is $1.48B.
How many shares of NVCR are outstanding?
Novocure has 116.79M shares outstanding. The count is up 4.36% from a year earlier.
Does NVCR pay a dividend?
No. Novocure does not pay a dividend.
How much debt does NVCR have?
Novocure has $196.34M of total debt and $96.73M of cash and equivalents, a net debt position of $99.60M.
NVCR pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts